My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Aptorum Group Limited - Class A Ordinary Shares (NQ:APM)

0.8400 +0.0500 (+6.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 Next >

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

February 10, 2023

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

February 06, 2023

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces 1-for-10 Reverse Stock Split

January 20, 2023

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

January 04, 2023

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

December 22, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

December 16, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

December 09, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

November 25, 2022

Via ACCESSWIRE

Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

November 25, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

November 18, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

November 08, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

September 30, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

September 23, 2022

Via ACCESSWIRE

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

September 15, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

September 15, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

August 25, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

August 19, 2022

Via ACCESSWIRE

The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1

July 25, 2022

Via ACN Newswire

Topics Intellectual Property

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

May 17, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

May 02, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

April 29, 2022

From Aptorum Group Limited

Via Business Wire

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted

April 25, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

April 22, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

January 20, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma

January 18, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

January 10, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers

January 10, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma

January 10, 2022

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

December 03, 2021

From Aptorum Group Limited

Via Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

October 19, 2021

From Aptorum Group Limited

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.